According to a recent LinkedIn post from Strive Health, the company is drawing attention to a reported link between chronic kidney disease and elevated risks of cognitive decline and dementia. The post notes that Chief Clinical Officer Syed Sumair Akhtar recently discussed this connection with DocWire News, emphasizing the importance of increased screening for cognitive issues in kidney disease patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights a care philosophy focused on treating the “whole person” and allowing more time for in-depth health conversations with the 37 million people reportedly living with kidney disease. For investors, this emphasis suggests Strive Health may be positioning its model as a differentiated, higher-touch approach that aligns with value-based care trends and could support long-term demand for its kidney care services.
The post also points readers to an external interview with Dr. Akhtar, which may help raise the company’s visibility among clinicians, payors, and potential partners. Increased awareness of the broader health implications of kidney disease could open opportunities for integrated care programs and collaborations, potentially enhancing Strive Health’s competitive standing in the specialized kidney care market.